Department of Gastroenterology, Okazaki City Medical Association Public Health Center, Okazaki, Japan.
Digestion. 2024;105(1):26-33. doi: 10.1159/000532082. Epub 2023 Aug 18.
Functional dyspepsia (FD) is a common disorder characterized by chronic or recurrent upper abdominal pain or discomfort without any structural abnormalities in the gastrointestinal tract. FD is categorized into two subgroups based on symptoms: postprandial distress syndrome (PDS) and epigastric pain syndrome.
The pathophysiology of FD involves several mechanisms. Delayed gastric emptying is observed in approximately 30% of FD patients but does not correlate with symptom patterns or severity. Impaired gastric accommodation is important in the pathophysiology, particularly for PDS. Visceral hypersensitivity, characterized by heightened sensitivity to normal activities, contributes to the perception of discomfort or pain in FD. Alterations to the duodenal mucosa, including impaired mucosal barrier function and low-grade inflammation, are also implicated in the pathogenesis of FD. Microbial dysbiosis and psychological factors such as stress can further exacerbate symptoms. Treatment options include dietary modifications, establishing a physician-patient relationship, acid suppressants, prokinetics, neuromodulators, and behavioral therapies. Dietary recommendations include eating smaller, more frequent meals, and avoiding trigger foods. Acid suppressants are used as the first-line treatment. Prokinetics and neuromodulators aim to improve gastric motility and central pain processing, respectively. Behavioral therapies, including cognitive behavioral therapy and hypnotherapy, have shown benefits for refractory FD. Severe and refractory cases may require combination therapies or experimental treatments.
FD is a disorder of gut-brain interaction involving diverse pathophysiological mechanisms. Individualized treatment based on symptoms and responses to interventions is crucial. Further research is needed to improve the understanding of FD and advance the development of effective therapies.
功能性消化不良(FD)是一种常见的疾病,其特征为慢性或复发性上腹部疼痛或不适,而胃肠道无结构异常。FD 根据症状可分为两个亚组:餐后不适综合征(PDS)和上腹疼痛综合征。
FD 的病理生理学涉及多种机制。大约 30%的 FD 患者存在胃排空延迟,但与症状模式或严重程度无关。胃容纳功能受损在病理生理学中很重要,特别是对于 PDS。内脏高敏感,表现为对正常活动的敏感性增加,导致 FD 患者出现不适或疼痛的感觉。十二指肠黏膜的改变,包括黏膜屏障功能受损和低度炎症,也与 FD 的发病机制有关。微生物失调和压力等心理因素也可加重症状。治疗选择包括饮食调整、医患关系建立、抑酸剂、促动力药、神经调节剂和行为疗法。饮食建议包括少吃多餐,避免触发食物。抑酸剂是一线治疗药物。促动力药和神经调节剂分别旨在改善胃动力和中枢疼痛处理。行为疗法,包括认知行为疗法和催眠疗法,对难治性 FD 有疗效。严重和难治性病例可能需要联合治疗或实验治疗。
FD 是一种涉及多种病理生理机制的肠-脑相互作用障碍。基于症状和干预反应的个体化治疗至关重要。需要进一步研究以提高对 FD 的认识并推进有效治疗方法的发展。